Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.40 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.35 |
| ▸ | PRNP | P04156 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466605 | 0.82 | RXFP1 (0.44) | PTPN2PTPN1NPC1RAB9AHPGD | |
| SCHEMBL29035358 | 0.77 | NPC1 (0.45) | PTPN2PTPN1KMT2AMEN1NPC1 | |
| SCHEMBL9099027 | 0.77 | PTPN2 (0.44) | PTPN2PTPN1KMT2AMEN1NPC1 | |
| SCHEMBL23931980 | 0.75 | PTPN2 (0.72) | PTPN2PTPN1KMT2AMEN1NPC1 | |
| SCHEMBL2948840 | 0.75 | MEN1 (0.50) | PTPN2PTPN1KMT2AMEN1NPC1 | |
| SCHEMBL5578107 | 0.75 | NPC1 (0.44) | PTPN2PTPN1KMT2AMEN1NPC1 | |
| SCHEMBL437283 | 0.73 | METAP1 (0.48) | KMT2AMEN1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1009157 | 0.71 | PTPN2 (0.43) | PTPN2PTPN1KMT2AMEN1NPC1 | |
| SCHEMBL15655404 | 0.71 | NPC1 (0.44) | PTPN2PTPN1KMT2AMEN1NPC1 | |
| SCHEMBL18047944 | 0.71 | MEN1 (0.40) | PTPN2PTPN1KMT2AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-07-11 | — | — | US | disclosed |
| WO-2024097855-A2 | IDENTIFICATION OF SMALL MOLECULES THAT RECRUIT AND ACTIVATE RNASE L | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2024-05-10 | — | — | WO | disclosed |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023170025-A1 | AMIDO CYCLOPROPYL DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-09-14 | — | — | WO | disclosed |
| US-20230250093-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2023-08-10 | — | — | US | disclosed |
| EP-4182301-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
| WO-2023085415-A1 | COMPOUND, ANGIOTENSIN-II TYPE 1 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION | 株式会社アークメディスン | 2023-05-19 | — | — | WO | disclosed |
| CN-115989220-A | Amido cyclohexanoic acid derivatives as LPA receptor inhibitors | 奇斯药制品公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022013378-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-01-20 | — | — | WO | disclosed |
| US-20210387998-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORPORATION | 2021-12-16 | — | — | US | disclosed |
| US-9181271-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2940013-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE Industries, Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2917221-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014071031-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20140121198-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION (US) | 2014-05-01 | — | — | US | disclosed |
| WO-2011079105-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| US-7696221-B2 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFκB inhibitors | WYETH LLC (US) | 2010-04-13 | — | — | US | disclosed |
| US-20060154875-A1 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors | WYETH (US) | 2006-07-13 | — | — | US | disclosed |
| WO-2006069182-A2 | THIENOISOQUINOLINE-PHENYLSULFONAMIDES AND THEIR USE AS ER-NFkB INHIBITORS | WYETH (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228508-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PTPN2 91/4885PTPN1 90/4885KMT2A 1139/4885 |
| US-20060154875-A1 | Thienoisoquinoline-phenylsulfonamides and their use as ER-NFkappaB inhibitors | NFKBIA, IKBKB, IKBKE | PTPN2 542/4885PTPN1 502/4885KMT2A 1542/4885 |
| US-20110152243-A1 | NOVEL THIENOPYRROLE COMPOUNDS | TPMT, TSLP, THPO | PTPN2 1069/4885PTPN1 1121/4885KMT2A 3648/4885 |
| US-11851442-B2 | Tricyclic fused thiophene derivatives as JAK inhibitors | JAK1, JAK3, JAK2 | PTPN2 91/4885PTPN1 90/4885KMT2A 1139/4885 |
| US-20140121198-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PTPN2 91/4885PTPN1 90/4885KMT2A 1139/4885 |
| US-20230250093-A1 | AMIDO CYCLOHEXANE ACID DERIVATIVES AS LPA RECEPTOR INHIBITORS | LPAR1, LPAR2, LPAR3 | PTPN2 1829/4885PTPN1 1076/4885KMT2A 3442/4885 |
| US-20210387998-A1 | TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | PTPN2 91/4885PTPN1 90/4885KMT2A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.